Loading…
Sectoral / Thematic · Nippon India Mutual Fund · AMFI code 102431Nippon India Pharma Fund
Disclosed for 84 months, Sep 2019 to Aug 2026.Published as: NIPPON INDIA PHARMA FUND (An Open Ended Equity Scheme Investing In Pharma Sector)
Portfolio value
₹9,044 Cr
up ₹408 Cr vs May 2026
Nippon India Pharma Fund is an active equity fund in the Sectoral / Thematic category from Nippon India Mutual Fund. In June 2026 it disclosed 35 stocks worth ₹9,044 Cr, up ₹408 Cr from May 2026. Its largest positions were Sun Pharmaceutical Industries Limited (12.8%), Lupin Limited (7.4%), Dr. Reddy's Laboratories Limited (6.7%); the ten largest together made up 58.1% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 73.7% of its equity. Cash and debt stood at 2.4%. Compared with May 2026 the fund entered 1 new stock and exited 0.
Against 229 other Sectoral / Thematic funds
Concentration
78%
Top-10 weight is higher than 78% of peers
Breadth
27%
Holds more stocks than 27% of peers
Cash
32%
Holds more cash than 32% of peers
What these mean: concentration · cash
Holdings in June 2026
Download CSVEvery line the fund disclosed, with the change against May 2026. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Sun Pharmaceutical Industries Limited | 12.78% | down 0.57 pts | ₹1,156 Cr | up ₹3.3 Cr | Held |
| Lupin Limited | 7.45% | up 0.14 pts | ₹673 Cr | up ₹42.1 Cr | Added |
| Dr. Reddy's Laboratories Limited | 6.68% | down 0.04 pts | ₹604 Cr | up ₹23.9 Cr | Added |
| Cipla Limited | 6.15% | down 0.01 pts | ₹556 Cr | up ₹24.4 Cr | Added |
| Divi's Laboratories Limited | 5.46% | down 0.33 pts | ₹494 Cr | down ₹6.6 Cr | Trimmed |
| Apollo Hospitals Enterprise Limited | 5.27% | up 0.07 pts | ₹476 Cr | up ₹27.7 Cr | Added |
| Mankind Pharma Limited | 4.03% | up 0.09 pts | ₹364 Cr | up ₹24.3 Cr | Added |
| Sai Life Sciences Limited | 3.49% | up 0.05 pts | ₹315 Cr | up ₹19 Cr | Added |
| Ajanta Pharma Limited | 3.46% | up 0.25 pts | ₹313 Cr | up ₹35.6 Cr | Added |
| Max Healthcare Institute Limited | 3.32% | up 0.35 pts | ₹300 Cr | up ₹43.6 Cr | Added |
| MedPlus Health Services Limited | 3.18% | down 0.50 pts | ₹287 Cr | down ₹29.9 Cr | Trimmed |
| Vijaya Diagnostic Centre Limited | 2.80% | down 0.41 pts | ₹253 Cr | down ₹23.9 Cr | Trimmed |
| Thyrocare Technologies Limited | 2.65% | up 0.09 pts | ₹240 Cr | up ₹18.8 Cr | Added |
| IPCA Laboratories Limited | 2.57% | up 0.16 pts | ₹232 Cr | up ₹24.1 Cr | Added |
| GlaxoSmithKline Pharmaceuticals Limited | 2.47% | up 0.14 pts | ₹224 Cr | up ₹21.9 Cr | Added |
| Cash, TREPS & receivables | 2.39% | up 0.31 pts | ₹216 Cr | up ₹36.2 Cr | Added |
| Gland Pharma Limited | 2.21% | up 0.12 pts | ₹200 Cr | up ₹19.6 Cr | Added |
| Abbott India Limited | 2.09% | down 0.22 pts | ₹189 Cr | down ₹10.5 Cr | Trimmed |
| Alkem Laboratories Limited | 1.99% | down 0.07 pts | ₹180 Cr | up ₹2.3 Cr | Added |
| Dr. Lal Path Labs Limited | 1.85% | down 0.04 pts | ₹168 Cr | up ₹4 Cr | Added |
| Narayana Hrudayalaya Limited | 1.80% | down 0.01 pts | ₹162 Cr | up ₹6.4 Cr | Added |
| Aurobindo Pharma Limited | 1.75% | down 0.57 pts | ₹158 Cr | down ₹41.8 Cr | Trimmed |
| Syngene International Limited | 1.70% | down 0.09 pts | ₹154 Cr | down ₹88 L | Trimmed |
| Pfizer Limited | 1.56% | down 0.13 pts | ₹141 Cr | down ₹5.1 Cr | Trimmed |
| Emcure Pharmaceuticals Limited | 1.52% | up 0.05 pts | ₹137 Cr | up ₹10.4 Cr | Added |
| Fortis Healthcare Limited | 1.42% | up 0.24 pts | ₹129 Cr | up ₹26.3 Cr | Added |
| Suraksha Diagnostic Limited | 1.18% | down 0.11 pts | ₹106 Cr | down ₹5 Cr | Trimmed |
| Sanofi Consumer Healthcare India Limited | 1.09% | down 0.05 pts | ₹98.2 Cr | up ₹18 L | Held |
| Akums Drugs and Pharmaceuticals Limited | 1.03% | up 0.11 pts | ₹92.8 Cr | up ₹13.3 Cr | Added |
| Piramal Pharma Limited | 1.02% | up 1.02 pts | ₹92.4 Cr | up ₹92.4 Cr | New |
| Anthem Biosciences Limited | 0.90% | down 0.03 pts | ₹81.6 Cr | up ₹1.1 Cr | Added |
| Sanofi India Limited | 0.87% | up 0.04 pts | ₹78.4 Cr | up ₹7.1 Cr | Added |
| Biocon Limited | 0.68% | down 0.05 pts | ₹61.5 Cr | down ₹1.5 Cr | Trimmed |
| AstraZeneca Pharma India Limited | 0.57% | down 0.06 pts | ₹51.5 Cr | down ₹2.5 Cr | Trimmed |
| Indoco Remedies Limited | 0.49% | up 0.04 pts | ₹43.9 Cr | up ₹5.4 Cr | Added |
| Concord Biotech Limited | 0.16% | up 0.02 pts | ₹14.3 Cr | up ₹2.6 Cr | Added |
What changed, May 2026 to Jun 2026
New New positions (1)
- Piramal Pharma Limited1.0% · ₹92.4 Cr
Exited Exited (0)
None.
Added Biggest additions
- Max Healthcare Institute Limitedup ₹43.6 Cr (+0.35% pts)
- Lupin Limitedup ₹42.1 Cr (+0.14% pts)
- Ajanta Pharma Limitedup ₹35.6 Cr (+0.25% pts)
- Apollo Hospitals Enterprise Limitedup ₹27.7 Cr (+0.07% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since May 2026, the weight rose most in Pharmaceuticals & Biotechnology (+0.3 pts) and Healthcare Services (+0.2 pts), and fell most in Retailing (−0.5 pts).
- Pharmaceuticals & Biotechnology73.4% → 73.7%+0.3 pts
- Healthcare Services22.4% → 22.5%+0.2 pts
- Retailing3.8% → 3.3%−0.5 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Jun 2023 | Jun 2025 | Dec 2025 | Mar 2026 | May 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 76.8% | 75.4% | 74.7% | 75.3% | 73.4% | 73.7% |
| Healthcare Services | 18.6% | 20.0% | 21.1% | 20.5% | 22.4% | 22.5% |
| Retailing | 3.1% | 3.8% | 3.6% | 3.9% | 3.8% | 3.3% |
| Pharmaceuticals | 1.2% | 0.7% | 0.5% | 0.4% | 0.5% | 0.5% |
Allocation in Jun 2026change vs May 2026
- Pharmaceuticals & Biotechnology (24)73.7%▲ 0.3 pts
- Healthcare Services (9)22.5%▲ 0.2 pts
- Retailing (1)3.3%▼ 0.5 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Jun 2026
2.4%
▲ 0.3 pts vs May 2026
- Cash alone
- 2.4%
- cash and net receivables
- A year earlier
- 0.5%
- Jun 2025 · now ▲ 1.9 pts
- Last 12 months
- 0.3% – 2.6%
- lowest to highest · record 5.9% in May 2021
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.